KẾT QUẢ ĐIỀU TRỊ UNG THƯ ĐẠI TRỰC TRÀNG DI CĂN BẰNG PHÁC ĐỒ FOLFIRI KẾT HỢP BEVACIZUMAB TẠI BỆNH VIỆN UNG BƯỚU TỈNH THANH HÓA

Abstract

Objective: To evaluate the treatment results of metastatic colorectal cancer using the FOLFIRI regimen combined with Bevacizumab at Thanh Hoa Provincial Oncology Hospital. Subjects and methods: Retrospective and prospective descriptive study of 52 patients diagnosed with metastatic colorectal cancer who received chemotherapy using the FOLFIRI regimen combined with bevacizumab at Thanh Hoa Provincial Oncology Hospital from June 2022 to January 2025. Research results: The average age of the study group is 62.46. The male/female ratio is 1.73/1. The rate of patients with risk factors is 13.46%. Patients with left-sided tumors account for a high percentage of 82.69%. The main reason for hospitalization is abdominal pain, accounting for 76.9%. Liver and lung metastases are the two most common locations, accounting for 65.38% and 51.91%. Most patients have increased CEA 67.3% and UTBMT accounts for 92.3%. The disease control rate is 80.8%, the overall response rate is 69.2%, the complete response is 35.6%. The response rate has a statistically significant difference when analyzed with factors: treatment step, cell differentiation and CEA concentration. Common adverse effects of the regimen are: neutropenia, decreased hemoglobin, thrombocytopenia, increased AST/ALT, increased Creatinine, vomiting and diarrhea, but mainly at grade 1, 2. The adverse effects of Bevacizumab are mainly high blood pressure and nosebleeds at a mild level and well controlled. Conclusion: The Bevacizumab combined with FOLFIRI regimen showed a high response rate and was well tolerated in patients with stage IV colorectal cancer, poor physical condition, elderly, and had acceptable adverse effects.